Difference between revisions of "Tigatuzumab (CS-1008)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Investigational" to "Category:Investigational drugs") |
Warner-admin (talk | contribs) m (Text replacement - "Category:Antibody medications" to "") |
||
| Line 4: | Line 4: | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
| − | + | ||
[[Category:Anti-TRAIL-R2 antibodies]] | [[Category:Anti-TRAIL-R2 antibodies]] | ||
[[Category:Investigational drugs]] | [[Category:Investigational drugs]] | ||
Revision as of 20:01, 27 February 2020
Mechanism of action
Monoclonal antibody directed against the tumour necrosis factor-related apoptosis-inducing ligand receptor 2 (TRAIL-R2)